Published in Cancer Weekly, September 11th, 2007
The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies.
Today, there are more than 170 companies plus partners developing more than 300 antibody based oncology drugs in more than 590 developmental projects. In all targeting around 50 different cancer indications. The number of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.